Campylobacter antimicrobial resistance in Peru: a ten-year observational study

Simon Pollett; Claudio Rocha; Rito Zerpa; Lilian Patiño; Augusto Valencia; Máximo Camiña; José Guevara; Martha Lopez; Nancy Chuquiray; Eduardo Salazar-Lindo; Carlos Calampa; Martín Casapia; Rina Meza; Maruja Bernal; Drake Tilley; Michael Gregory; Ryan Maves; Eric Hall; Franca Jones; C. S. Arriola; Marieke Rosenbaum; Juan Perez; Matthew Kasper

doi:10.1186/1471-2334-12-193

Campylobacter antimicrobial resistance in Peru: a ten-year observational study

Simon Pollett, Claudio Rocha, Rito Zerpa, Lilian Patiño, Augusto Valencia, Máximo Camiña, José Guevara, Martha Lopez, Nancy Chuquiray, Eduardo Salazar-Lindo, Carlos Calampa, Martín Casapia, Rina Meza, Maruja Bernal, Drake Tilley, Michael Gregory, Ryan Maves, Eric Hall, Franca Jones, C. S. ArriolaMarieke Rosenbaum, Juan Perez, Matthew Kasper

Research output: Contribution to journal › Article › peer-review

54 Scopus citations

Abstract

Background: Campylobacter jejuni and Campylobacter coli are food-borne pathogens of great importance and feature prominently in the etiology of developing world enteritis and travellers' diarrhoea. Increasing antimicrobial resistant Campylobacter prevalence has been described globally, yet data from Peru is limited. Our objective was to describe the prevalence trends of fluoroquinolone and macrolide-resistant C. jejuni and C. coli stool isolates from three regions in Peru over a ten-year period.Methods: Surveillance for enteric pathogens was conducted in Lima, Iquitos and Cusco between 2001 and 2010. Campylobacter stool isolates were tested for susceptibilities to ciprofloxacin, azithromycin and erythromycin. Susceptibilities were reviewed for 4652 isolates from Lima ( n = 3419), Iquitos ( n = 625) and Cusco ( n = 608).Results: Comparing the study periods of 2001-2005 and 2006-2010, prevalence of ciprofloxacin-resistant C. jejuni isolates rose in the study areas of Lima (73.1% to 89.8%, p < 0.001) and Iquitos (24.1% to 48.9%, p < 0.001). Ciprofloxacin-resistant C. coli rates also increased in Lima (48.1% to 87.4%, p < 0.001) and Cusco (10.0% to 65.9%, p = 0.005). Small but significant increases in azithromycin-resistant and erythromycin-resistant C. jejuni prevalence were noted in Iquitos (2.2% to 14.9%, p < 0.001; 3.2% to 14.9%, p = 0.002), and erythromycin-resistant C. coli rates increased in Lima (0.0% to 5.3%, p = 0.038). The prevalence of C. jejuni isolates resistant to both ciprofloxacin and azithromycin increased in Iquitos (0.3% to 14.9%, p < 0.001) and Lima (0.3% to 1.6%, p = 0.011), and prevalence of C. jejuni isolates resistant to both ciprofloxacin and erythromycin rose in Iquitos (0.0% to 14.9%, p < 0.001). Ciprofloxacin and erythromycin resistant C. coli prevalence increased in Lima (0.0% to 5.3%, p = 0.034).Conclusions: These results have implications for the empirical management of enterocolitis in Peru. Ongoing surveillance is essential to guide appropriate antimicrobial use in this setting. Local epidemiological studies to explore the relationship between increasing antimicrobial resistance and agricultural or human antibiotic use may be valuable.

Original language	English
Article number	193
Journal	BMC Infectious Diseases
Volume	12
DOIs	https://doi.org/10.1186/1471-2334-12-193
State	Published - 16 Aug 2012

Bibliographical note

Funding Information:
This work was funded by U.S. Department of Defense’s Global Emerging Infection Systems (DoD-GEIS), a division of the Armed Forces Health Surveillance Center (AFHSC), and by the Military Infectious Disease Research Program (DOD-MIDRP). Aspects of this data and manuscript were presented in the form of a Scientific Poster at the 60th American Society of Tropical Medicine and Hygiene Conference, December 2011. The authors would like to thank Javier Soto for his assistance with laboratory procedures.

Keywords

Antibiotic resistance
Campylobacter
Fluoroquinolones
Macrolides
Peru

Access to Document

10.1186/1471-2334-12-193

Cite this

Pollett, S., Rocha, C., Zerpa, R., Patiño, L., Valencia, A., Camiña, M., Guevara, J., Lopez, M., Chuquiray, N., Salazar-Lindo, E., Calampa, C., Casapia, M., Meza, R., Bernal, M., Tilley, D., Gregory, M., Maves, R., Hall, E., Jones, F., ... Kasper, M. (2012). Campylobacter antimicrobial resistance in Peru: a ten-year observational study. BMC Infectious Diseases, 12, Article 193. https://doi.org/10.1186/1471-2334-12-193

@article{f24c72a2304647c4b51eae7f9ab8278f,

title = "Campylobacter antimicrobial resistance in Peru: a ten-year observational study",

abstract = "Background: Campylobacter jejuni and Campylobacter coli are food-borne pathogens of great importance and feature prominently in the etiology of developing world enteritis and travellers' diarrhoea. Increasing antimicrobial resistant Campylobacter prevalence has been described globally, yet data from Peru is limited. Our objective was to describe the prevalence trends of fluoroquinolone and macrolide-resistant C. jejuni and C. coli stool isolates from three regions in Peru over a ten-year period.Methods: Surveillance for enteric pathogens was conducted in Lima, Iquitos and Cusco between 2001 and 2010. Campylobacter stool isolates were tested for susceptibilities to ciprofloxacin, azithromycin and erythromycin. Susceptibilities were reviewed for 4652 isolates from Lima ( n = 3419), Iquitos ( n = 625) and Cusco ( n = 608).Results: Comparing the study periods of 2001-2005 and 2006-2010, prevalence of ciprofloxacin-resistant C. jejuni isolates rose in the study areas of Lima (73.1% to 89.8%, p < 0.001) and Iquitos (24.1% to 48.9%, p < 0.001). Ciprofloxacin-resistant C. coli rates also increased in Lima (48.1% to 87.4%, p < 0.001) and Cusco (10.0% to 65.9%, p = 0.005). Small but significant increases in azithromycin-resistant and erythromycin-resistant C. jejuni prevalence were noted in Iquitos (2.2% to 14.9%, p < 0.001; 3.2% to 14.9%, p = 0.002), and erythromycin-resistant C. coli rates increased in Lima (0.0% to 5.3%, p = 0.038). The prevalence of C. jejuni isolates resistant to both ciprofloxacin and azithromycin increased in Iquitos (0.3% to 14.9%, p < 0.001) and Lima (0.3% to 1.6%, p = 0.011), and prevalence of C. jejuni isolates resistant to both ciprofloxacin and erythromycin rose in Iquitos (0.0% to 14.9%, p < 0.001). Ciprofloxacin and erythromycin resistant C. coli prevalence increased in Lima (0.0% to 5.3%, p = 0.034).Conclusions: These results have implications for the empirical management of enterocolitis in Peru. Ongoing surveillance is essential to guide appropriate antimicrobial use in this setting. Local epidemiological studies to explore the relationship between increasing antimicrobial resistance and agricultural or human antibiotic use may be valuable.",

keywords = "Antibiotic resistance, Campylobacter, Fluoroquinolones, Macrolides, Peru",

author = "Simon Pollett and Claudio Rocha and Rito Zerpa and Lilian Pati{\~n}o and Augusto Valencia and M{\'a}ximo Cami{\~n}a and Jos{\'e} Guevara and Martha Lopez and Nancy Chuquiray and Eduardo Salazar-Lindo and Carlos Calampa and Mart{\'i}n Casapia and Rina Meza and Maruja Bernal and Drake Tilley and Michael Gregory and Ryan Maves and Eric Hall and Franca Jones and Arriola, {C. S.} and Marieke Rosenbaum and Juan Perez and Matthew Kasper",

note = "Funding Information: This work was funded by U.S. Department of Defense{\textquoteright}s Global Emerging Infection Systems (DoD-GEIS), a division of the Armed Forces Health Surveillance Center (AFHSC), and by the Military Infectious Disease Research Program (DOD-MIDRP). Aspects of this data and manuscript were presented in the form of a Scientific Poster at the 60th American Society of Tropical Medicine and Hygiene Conference, December 2011. The authors would like to thank Javier Soto for his assistance with laboratory procedures.",

year = "2012",

month = aug,

day = "16",

doi = "10.1186/1471-2334-12-193",

language = "Ingl{\'e}s",

volume = "12",

journal = "BMC Infectious Diseases",

issn = "1471-2334",

publisher = "BioMed Central Ltd.",

}

Pollett, S, Rocha, C, Zerpa, R, Patiño, L, Valencia, A, Camiña, M, Guevara, J, Lopez, M, Chuquiray, N, Salazar-Lindo, E, Calampa, C, Casapia, M, Meza, R, Bernal, M, Tilley, D, Gregory, M, Maves, R, Hall, E, Jones, F, Arriola, CS, Rosenbaum, M, Perez, J & Kasper, M 2012, 'Campylobacter antimicrobial resistance in Peru: a ten-year observational study', BMC Infectious Diseases, vol. 12, 193. https://doi.org/10.1186/1471-2334-12-193

TY - JOUR

T1 - Campylobacter antimicrobial resistance in Peru

T2 - a ten-year observational study

AU - Pollett, Simon

AU - Rocha, Claudio

AU - Zerpa, Rito

AU - Patiño, Lilian

AU - Valencia, Augusto

AU - Camiña, Máximo

AU - Guevara, José

AU - Lopez, Martha

AU - Chuquiray, Nancy

AU - Salazar-Lindo, Eduardo

AU - Calampa, Carlos

AU - Casapia, Martín

AU - Meza, Rina

AU - Bernal, Maruja

AU - Tilley, Drake

AU - Gregory, Michael

AU - Maves, Ryan

AU - Hall, Eric

AU - Jones, Franca

AU - Arriola, C. S.

AU - Rosenbaum, Marieke

AU - Perez, Juan

AU - Kasper, Matthew

N1 - Funding Information: This work was funded by U.S. Department of Defense’s Global Emerging Infection Systems (DoD-GEIS), a division of the Armed Forces Health Surveillance Center (AFHSC), and by the Military Infectious Disease Research Program (DOD-MIDRP). Aspects of this data and manuscript were presented in the form of a Scientific Poster at the 60th American Society of Tropical Medicine and Hygiene Conference, December 2011. The authors would like to thank Javier Soto for his assistance with laboratory procedures.

PY - 2012/8/16

Y1 - 2012/8/16

N2 - Background: Campylobacter jejuni and Campylobacter coli are food-borne pathogens of great importance and feature prominently in the etiology of developing world enteritis and travellers' diarrhoea. Increasing antimicrobial resistant Campylobacter prevalence has been described globally, yet data from Peru is limited. Our objective was to describe the prevalence trends of fluoroquinolone and macrolide-resistant C. jejuni and C. coli stool isolates from three regions in Peru over a ten-year period.Methods: Surveillance for enteric pathogens was conducted in Lima, Iquitos and Cusco between 2001 and 2010. Campylobacter stool isolates were tested for susceptibilities to ciprofloxacin, azithromycin and erythromycin. Susceptibilities were reviewed for 4652 isolates from Lima ( n = 3419), Iquitos ( n = 625) and Cusco ( n = 608).Results: Comparing the study periods of 2001-2005 and 2006-2010, prevalence of ciprofloxacin-resistant C. jejuni isolates rose in the study areas of Lima (73.1% to 89.8%, p < 0.001) and Iquitos (24.1% to 48.9%, p < 0.001). Ciprofloxacin-resistant C. coli rates also increased in Lima (48.1% to 87.4%, p < 0.001) and Cusco (10.0% to 65.9%, p = 0.005). Small but significant increases in azithromycin-resistant and erythromycin-resistant C. jejuni prevalence were noted in Iquitos (2.2% to 14.9%, p < 0.001; 3.2% to 14.9%, p = 0.002), and erythromycin-resistant C. coli rates increased in Lima (0.0% to 5.3%, p = 0.038). The prevalence of C. jejuni isolates resistant to both ciprofloxacin and azithromycin increased in Iquitos (0.3% to 14.9%, p < 0.001) and Lima (0.3% to 1.6%, p = 0.011), and prevalence of C. jejuni isolates resistant to both ciprofloxacin and erythromycin rose in Iquitos (0.0% to 14.9%, p < 0.001). Ciprofloxacin and erythromycin resistant C. coli prevalence increased in Lima (0.0% to 5.3%, p = 0.034).Conclusions: These results have implications for the empirical management of enterocolitis in Peru. Ongoing surveillance is essential to guide appropriate antimicrobial use in this setting. Local epidemiological studies to explore the relationship between increasing antimicrobial resistance and agricultural or human antibiotic use may be valuable.

AB - Background: Campylobacter jejuni and Campylobacter coli are food-borne pathogens of great importance and feature prominently in the etiology of developing world enteritis and travellers' diarrhoea. Increasing antimicrobial resistant Campylobacter prevalence has been described globally, yet data from Peru is limited. Our objective was to describe the prevalence trends of fluoroquinolone and macrolide-resistant C. jejuni and C. coli stool isolates from three regions in Peru over a ten-year period.Methods: Surveillance for enteric pathogens was conducted in Lima, Iquitos and Cusco between 2001 and 2010. Campylobacter stool isolates were tested for susceptibilities to ciprofloxacin, azithromycin and erythromycin. Susceptibilities were reviewed for 4652 isolates from Lima ( n = 3419), Iquitos ( n = 625) and Cusco ( n = 608).Results: Comparing the study periods of 2001-2005 and 2006-2010, prevalence of ciprofloxacin-resistant C. jejuni isolates rose in the study areas of Lima (73.1% to 89.8%, p < 0.001) and Iquitos (24.1% to 48.9%, p < 0.001). Ciprofloxacin-resistant C. coli rates also increased in Lima (48.1% to 87.4%, p < 0.001) and Cusco (10.0% to 65.9%, p = 0.005). Small but significant increases in azithromycin-resistant and erythromycin-resistant C. jejuni prevalence were noted in Iquitos (2.2% to 14.9%, p < 0.001; 3.2% to 14.9%, p = 0.002), and erythromycin-resistant C. coli rates increased in Lima (0.0% to 5.3%, p = 0.038). The prevalence of C. jejuni isolates resistant to both ciprofloxacin and azithromycin increased in Iquitos (0.3% to 14.9%, p < 0.001) and Lima (0.3% to 1.6%, p = 0.011), and prevalence of C. jejuni isolates resistant to both ciprofloxacin and erythromycin rose in Iquitos (0.0% to 14.9%, p < 0.001). Ciprofloxacin and erythromycin resistant C. coli prevalence increased in Lima (0.0% to 5.3%, p = 0.034).Conclusions: These results have implications for the empirical management of enterocolitis in Peru. Ongoing surveillance is essential to guide appropriate antimicrobial use in this setting. Local epidemiological studies to explore the relationship between increasing antimicrobial resistance and agricultural or human antibiotic use may be valuable.

KW - Antibiotic resistance

KW - Campylobacter

KW - Fluoroquinolones

KW - Macrolides

KW - Peru

UR - http://www.scopus.com/inward/record.url?scp=84864913317&partnerID=8YFLogxK

U2 - 10.1186/1471-2334-12-193

DO - 10.1186/1471-2334-12-193

M3 - Artículo

C2 - 22898609

AN - SCOPUS:84864913317

SN - 1471-2334

VL - 12

JO - BMC Infectious Diseases

JF - BMC Infectious Diseases

M1 - 193

ER -

Campylobacter antimicrobial resistance in Peru: a ten-year observational study

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this